Action Quest PharmaTech - QPT

Quest PharmaTech Inc (QPT) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,02

( -20,00% )

Prix Achat

0,02

Prix Vente

0,025

Volume échangé

155 100

Volume moyen (3 m)

$ 83 175

Volume financier

0,02 Fourchette du Jour 0,02

0,02 Plage de 52 semaines 0,05

Cap du marché

3,383M

Valeur d'Entreprise

5,214M

Clôture Veille

0,025

Ouverture

0,02

Dernière Transaction

55000

0.02

Dernière heure de transaction

VWAP

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

Actions en circulation

169 129 247

Flottant (%)

82,04%

Détention Institutionnelle (%)

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

0,85

Ratio Cours/Ventes (P/S)

Bénéfice par action (BPA)

0,03

Bêta

-0,3

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada. Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.

Secteur

Health Care

Industrie

Site Web

www.questpharmatech.com

Siège social

Edmonton, Canada

Fondé

Quest PharmaTech Inc est coté dans le secteur Health Care de la TSX Venture Exchange avec le ticker QPT. Le dernier cours de clôture d'Quest PharmaTech était de $0,03. Au cours de la dernière année, les actions de Quest PharmaTech ont été négociées dans une fourchette de prix de $ 0,02 à $ 0,05.

Quest PharmaTech compte actuellement 169 129 247 actions en circulation. La capitalisation boursière d'Quest PharmaTech est de $3,38 million. Quest PharmaTech a un ratio cours/bénéfice (ratio PE) de 0.85.

Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis

EDMONTON, Alberta, May 29, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the...

Quest PharmaTech Announces Results from AGM

EDMONTON, Alberta, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the...

Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the...

Quest PharmaTech Provides Corporate Update

EDMONTON, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the...

Quest PharmaTech Announces Results from AGM

EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the...

Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director

Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New...

Quest Receives Cash Dividend Payment from OncoQuest

Quest Receives Cash Dividend Payment from OncoQuest Canada NewsWire EDMONTON, AB, Jan. 30, 2024 EDMONTON, AB, Jan. 30, 2024 /CNW/ - Quest...

Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits

Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential...

Quest PharmaTech Provides Corporate Update

Quest PharmaTech Provides Corporate Update Canada NewsWire EDMONTON, AB, Sept. 13, 2023 EDMONTON, AB, Sept. 13, 2023 /CNW/ - Quest PharmaTech...

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Announces Results from AGM Canada NewsWire EDMONTON, AB, July 14, 2023 EDMONTON, AB, July 14, 2023 /CNW/ - Quest PharmaTech Inc...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.005	-20	0.025	0.025	0.02	41960	0.025	CS
4	-0.015	-42.8571428571	0.035	0.04	0.02	106904	0.0221619	CS
12	-0.015	-42.8571428571	0.035	0.04	0.02	51602	0.02670999	CS
26	-0.015	-42.8571428571	0.035	0.04	0.02	38154	0.02847511	CS
52	-0.015	-42.8571428571	0.035	0.05	0.02	28039	0.03186746	CS
156	-0.06	-75	0.08	0.095	0.015	30257	0.03352202	CS
260	-0.075	-78.9473684211	0.095	0.165	0.015	27141	0.0508732	CS

QPT - Frequently Asked Questions (FAQ)

What is the current Quest PharmaTech Inc share price?

The current share price of Quest PharmaTech Inc is $ 0,02

How many Quest PharmaTech Inc shares are in issue?

Quest PharmaTech Inc has 169 129 247 shares in issue

What is the market cap of Quest PharmaTech Inc?

The market capitalisation of Quest PharmaTech Inc is CAD 3,38M

What is the 1 year trading range for Quest PharmaTech Inc share price?

Quest PharmaTech Inc has traded in the range of $ 0,02 to $ 0,05 during the past year

What is the PE ratio of Quest PharmaTech Inc?

The price to earnings ratio of Quest PharmaTech Inc is 0,85

What is the registered address of Quest PharmaTech Inc?

The registered address for Quest PharmaTech Inc is 97 Street NW, Edmonton, Alberta, T6E 5R9

What is the Quest PharmaTech Inc website address?

The website address for Quest PharmaTech Inc is www.questpharmatech.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quest PharmaTech Inc (QPT)

Quest PharmaTech Inc (QPT) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Quest PharmaTech Inc

QPT Dernières nouvelles

Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

Quest PharmaTech Provides Corporate Update

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director

Quest Receives Cash Dividend Payment from OncoQuest

Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits

Quest PharmaTech Provides Corporate Update

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis

Quest PharmaTech Announces Results from AGM

QPT - Frequently Asked Questions (FAQ)

QPT Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quest PharmaTech Inc (QPT)

Quest PharmaTech Inc (QPT) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Quest PharmaTech Inc

QPT Dernières nouvelles

Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

Quest PharmaTech Provides Corporate Update

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director

Quest Receives Cash Dividend Payment from OncoQuest

Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits

Quest PharmaTech Provides Corporate Update

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis

Quest PharmaTech Announces Results from AGM

QPT - Frequently Asked Questions (FAQ)

QPT Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités